Thalidomide: Lack of mutagenic activity across phyla and genetic endpoints

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 396, Issue 1-2, 1997, Pages 45-64

  Ashby, J ^a   Tinwell, H ^a   Callander, R D ^a   Kimber, I ^a   Clay, P ^a   Galloway, S M ^b   Hill, R B ^b   Greenwood, S K ^b   Gaulden, M E ^c   Ferguson, M J ^c   Vogel, E ^d   Nivard, M ^d   Parry, J M ^e   Williamson, J ^e  

^a ASTRAZENECA   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

^e SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLASTOGEN; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CYTOTOXICITY; DROSOPHILA MELANOGASTER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MOUSE; MUTAGEN TESTING; MUTAGENIC ACTIVITY; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SALMONELLA;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; BIOTRANSFORMATION; CELLS, CULTURED; CHO CELLS; CHROMOSOME ABERRATIONS; CRICETINAE; DROSOPHILA MELANOGASTER; FEMALE; GRASSHOPPERS; HUMANS; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICRONUCLEUS TESTS; MICROSOMES, LIVER; MUTAGENICITY TESTS; NEURONS; PREGNANCY; RABBITS; RATS; SALMONELLA TYPHIMURIUM; SPECIES SPECIFICITY; STEM CELLS; TERATOGENS; THALIDOMIDE;

EID: 17644432448     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00174-7     Document Type: Article

References (59)

1. McBride W.G. Thalidomide may be a mutagen. British Medical Journal. 308:1994;1635-1636.
2. McBride W.G. Thalidomide and congenital abnormalities. Lancet. 2:1961;1358.
3. Hayman D.J. Distaval. Lancet. 2:1961;1262.
4. Kemper F. Thalidomide and congenital abnormalities. Lancet. 2:1962;836.
5. Hughes D.T., Delhanty J.D.A., Chitham R.G., Playfair J.H.L., Hopper P.K. Chromosomes of thalidomide-deformed foetuses. Lancet. 2:1962;836-837.
6. Lüers H. Failure of mutagenic action of thalidomide in Drosophila. Lancet. 2:1962;1332.
7. Amirkhanian J.D. Thalidomide as a mutagenic agent to the mosquito (Culex pipiens molestus). Experientia. 26:1970;796-799.
8. Epstein S.S., Arnold E., Andrea J., Bass W., Bishop Y. Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. Appl. Pharmacol. 23:1972;288-325.
9. D. MacKenzie, Secret tests say thalidomide is mutagenic, New Scientist, 18 August (1983) 457.
10. L. Flohé and E. Frankus, Thalidomide (Letter), New Scientist (1983). 49.
11. Read A.P. Thalidomide may be a mutagen. Br. Med. J. 308:1994;1636. Comment.
12. Smithells R.W. Thalidomide may be a mutagen. Br. Med. J. 309:1994;477.
13. Kida M. Thalidomide may not be a mutagen. Br. Med. J. 309:1994;741.
14. Ashby J., Tinwell H. Is thalidomide mutagenic? Nature. 375:1995;453.
15. Flint O. Smoke signals. Nature. 382:1996;572.
16. Ashby J. Smoke signals. Nature. 383:1996;474.
17. J. Aitken, Thalidomide: The next generation, the case for, Daily Mail, March 24 (1995), 24 pp.
18. C. Newman, Thalidomide: The next generation, the case against, Daily Mail, March 24 (1995) 24 pp.
19. Zwingenberger K., Wnendt S. Immunomodulation by thalidomide - Systematic review of the literature and of unpublished observations. J. Inflammation. 46:1996;177-211.
20. Cimons M. Thalidomide resurfaces for FDA consideration. Nature Med. 3:1997;8.
21. Ashby J., Callander R.D., Rose F.L. Weak mutagenicity to Salmonella of the formaldehyde releasing anti-tumour agent hexamethylmelamine. Mutation Res. 142:1985;121-125.
22. Tinwell H., Ashby J. Comparison of acridine orange and Giemsa stains in several mouse bone marrow micronucleus assays: including a triple dose experiment. Mutagenesis. 4:1989;477-482.
23. Ames B.N., McCann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Res. 31:1975;347-364.
24. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutation Res. 113:1983;173-215.
25. Lefevre P.A., Ashby J. The effects of pre-incubation period and norharman on the mutagenic potency of 4-dimethylaminobenzene and 3′-methyl-4-dimethylaminobenzene. Carcinogenesis. 2:1981;927-931.
26. Venitt S., Crofton Sleigh C., Osborne M.R. The hair-dye reagent 2-(2′,4′-diaminophenoxy)ethanol is mutagenic to Salmonella typhimurium. Mutation Res. 135:1984;31-47.
27. Johnson T.E., Umbenhauer D.R., Galloway S.M. Human liver S-9 metabolic activation: Proficiency in cytogenetic assays and comparison with Phenobarbital/β-naphthoflavone or Aroclor 1254 induced rat S-9. Environ. Mol. Mutagen. 28:1996;51-59.
28. Gordon G.B., Spielberg S.P., Blake D.A., Balasubramanian V. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA. 78:1981;2545-2548.
29. Spielberg S.P. Acetaminophen toxicity in human lymphocytes in vitro. J. Pharmacol. Exp. Ther. 213:1980;395-398.
30. Ellard S., Parry E.M. A modified protocol for the cytochalasin B in vitro micronucleus assay using whole human blood or separated lymphocyte cultures. Mutagenesis. 8:1993;317-320.
31. +/- mouse lymphoma cells. Mutagenesis. 5(Supp):1990;45-54.
32. Callander R.D., Mackay J.M., Clay P., Elcombe C.R., Elliott B.M. Evaluation of phenobarbital/β-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays. Mutagenesis. 10:1995;517-522.
33. Vogel E.W., Nivard M.J.M. Performance of 181 chemicals in a Drosophila assay predominantly monitoring interchromosomal mitotic recombination. Mutagenesis. 8:1993;57-81.
34. M.E. Gaulden, J.C. Liang, M.J. Ferguson, The grasshopper neuroblast short-term assay for evaluating the effects of environmental chemicals on chromosomes and cell kinetics, in: F.J. de Serres (Ed.), Chemical Mutagens, Vol. 9, Plenum, New York, 1984, pp. 1-65.
35. Ashby J. The efficient preparation of corn oil suspensions. Mutation Res. 187:1987;45.
36. Tinwell H., Ashby J. Genetic toxicity and potential carcinogenicity of taxol. Carcinogenesis. 15:1994;1499-1501.
37. +/- cells. Environ. Mol. Mutagen. 24:1994;51-60.
38. Sheldon T., Richardson C.R., Elliott B.M. Inactivity of methylene chloride in the mouse bone marrow micronucleus assay. Mutagenesis. 2:1987;57-59.
39. H.A. Hartman, The fetus in experimental teratology, in: S.H. Weisbroth, R.E. Flatt, A.L. Kraus (Eds.), The Biology of the Laboratory Rabbit, Academic Press, New York, 1974, pp. 95-142.
40. Kimber I., Basketter D.A. The murine local lymph node assay: a commentary on collaborative studies and new directions. Fd. Chem. Toxicol. 30:1992;165-169.
41. Roux C., Emerit I., Taillemite J.L. Chromosomal breakage and teratogenesis. Teratology. 4:1971;303-316.
42. Jensen M.K. Chromosome aberrations in human cells induced by thalidomide in vitro. Acta Med. Scand. 177:1965;783-784.
43. Zúñiga G., Torres-Bugarín O., Ramírez-Muñoz M.P., Ramos A., Fanti-Rodríguez E., Portilla E., García-Martínez D., Cantú J.M., Gallegos-Arreola M.P., Sánchez-Corona J. Spontaneous micronuclei in peripheral blood erythrocytes from 35 mammalian species. Mutation Res. 369:1996;123-127.
44. Benda C.E., Baughman F.A. Slight aneuploidy and multiple CA in the peripheral blood of thalidomide victims. Med. Welt. 2:1963;1661.
45. Roe F.J.C., Mitchley B.C.V. Thalidomide and neoplasia. Nature. 200:1963;1016-1017.
46. Giacomello G., Malatesta P., Quaglia G. Action of thalidomide on radical meristems of Allium cepa. Nature. 201:1964;940-941.
47. Borghi S., Botrè C., Ciconetti P., Mazzeo P. Interazione della D-ed L-2-ftalimmido-glutarimmide con acido desossiribonucleico (DNA) ed acido ribonucleico solubile (sRNA). Farmaco. Ed. Sci. 21:1966;723-727.
48. Natarajan A.T., Nilsson R. The cytological effects of thalidomide and its hydrolytic products. Naturwisssenschaften. 53:1966;275-276.
49. Soukup S., Takacs E., Warkany J. Chromosome changes in embryos treated with various teratogens. J. Embryol. Exp. Morphol. 182:1967;215-226.
50. Bakay B., Nyhan W.L. Binding of thalidomide by macromolecules in the fetal and maternal rat. J. Pharmacol. Exp. Ther. 161:1968;348-360.
51. Gordon G. Mutagenic and cytotoxic studies with thalidomide. Diss. Abstr. Int. 42:1981;1415.
52. Ashby J., Waters M.D., Preston J., Adler I.D., Douglas G.R., Fielder R., Shelby M.D., Anderson D., Sofuni T., Gopalan H.N.B., Becking G., Sonich-Mullin C. IPCS harmonization of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mechanism of action of carcinogens. Mutation Res. 352:1996;153-157.
53. Shelby M.D. Selecting chemicals and assays for assessing mammalian germ cell mutagenicity. Mutation Res. 352:1996;159-167.
54. Somers G.F. Thalidomide and congenital abnormalities. Lancet. 2:1962;912-913.
55. Tinwell H., Ashby J. Micronucleus morphology as a means to distinguish aneugens and clastogens in the mouse bone marrow micronucleus assay. Mutagenesis. 6:1991;193-198.
56. Parry J.M., Natarajan A.T. Detection of aneugenic chemicals: EEC Project. Mutation Res. 287:1993;1-139.
57. Ashby J., Hilton J., Dearman R.J., Callander R.D., Kimber I. Mechanistic relationship between mutagenicity, skin sensitization and skin carcinogenicity. Environ. Health Perspect. 101:1993;62-67.
58. Hill R.B., Greenwood S.K., Galloway S.M. Thalidomide does not induce chromosome aberrations in vitro. Environ. Mol. Mutagen. 27(27):1996;30.
59. +/- mouse lymphoma cells. Environ. Mol. Mutagen. 29(28):1997;10.